Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773931 | 1.00 | PTPN1 (0.54) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL864823 | 1.00 | PTPN1 (0.54) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL4012499 | 1.00 | PTPN1 (0.54) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL29502321 | 1.00 | PTPN1 (0.54) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL30254985 | 1.00 | PTPN1 (0.54) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL546157 | 0.95 | ESR2 (0.56) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL2722678 | 0.89 | PTPN1 (0.53) | PTPN1HDAC8 | |
| SCHEMBL30592013 | 0.88 | PTPN1 (0.69) | PTPN1ESR2HDAC8 | |
| SCHEMBL29369360 | 0.88 | PTPN1 (0.69) | PTPN1ESR2HDAC8 | |
| SCHEMBL17486413 | 0.88 | PTPN1 (0.69) | PTPN1ESR2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240057599-A1 | METHODS FOR IMPROVING FRUIT QUALITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2024-02-22 | — | — | US | disclosed |
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11812746-B2 | Method of controlling fungal infections in plants | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2023-11-14 | — | — | US | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3601258-B1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-110461829-B | Substituted isoquinoline derivatives as immunomodulators | 百时美施贵宝公司 | 2023-02-28 | — | — | CN | disclosed |
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | RESEARCH TRIANGLE INSTITUTE (NC) | 2022-04-05 | — | — | US | disclosed |
| US-11046675-B2 | Substituted isoquionline derivatives as immunomudulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200383327-A1 | METHOD OF IMPROVING PLANT PERFORMANCE | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2020-12-10 | — | — | US | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| WO-2013086200-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2013-06-13 | — | — | WO | disclosed |
| CN-101355951-B | Novel opioid antagonists | ADOLOR CORP | 2013-03-27 | — | — | CN | disclosed |
| US-8278323-B2 | Opioid antagonists | ADOLOR CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120231543-A1 | NOVEL OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| US-20090221562-A1 | NOVEL OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2009-09-03 | — | — | US | disclosed |
| US-7538110-B2 | e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction | ADOLOR CORPORATION (US) | 2009-05-26 | — | — | US | disclosed |
| CN-101355951-A | Novel opioid antagonists | ADOLOR CORP (US) | 2009-01-28 | — | — | CN | disclosed |
| US-20070105863-A1 | e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | disclosed |
| US-20070105863-A1 | e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | disclosed |
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120231543-A1 | NOVEL OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRL1 | PTPN1 3366/4885ESR2 1159/4885OPRM1 2/4885 |
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | PTPN1 2698/4885ESR2 1522/4885OPRM1 8/4885 |
| US-20090221562-A1 | NOVEL OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRL1 | PTPN1 3366/4885ESR2 1159/4885OPRM1 2/4885 |
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | OPRK1, OPRD1, OPRM1 | PTPN1 1493/4885ESR2 400/4885OPRM1 3/4885 |
| US-11046675-B2 | Substituted isoquionline derivatives as immunomudulators | CD74, HLA-DRB1, ICOS | PTPN1 205/4885ESR2 2751/4885OPRM1 1347/4885 |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, NR1H2 | PTPN1 1570/4885ESR2 92/4885OPRM1 317/4885 |
| US-20070105863-A1 | e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction | OPRK1, OPRD1, OPRM1 | PTPN1 2108/4885ESR2 773/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.